DeepMed Research

MASSACHUSETTS GENERAL HOSPITAL

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1811-01-01

Employees: -

Market Cap: -

Website: http://www.massgeneral.org/international

Clinical Trials

The Effects of Aging and Estrogen on the Pituitary

Phase 2

Conditions: Healthy

Interventions: Drug: GnRH
Drug: NAL-GLU GnRH antagonist
Drug: Estrogen patch

First Posted Date: 2006-10-11

Last Posted Date: 2017-04-13

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 19

Registration Number: NCT00386022

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

PTK787/ZK 222584 in Combination With Temozolomide and Radiation in Patients With Glioblastoma Taking Enzyme-Inducing Anti-Epileptic Drugs

Phase 1

Completed

Conditions: Glioblastoma

Interventions: Drug: PTK787/ZK 222584
Drug: Temozolomide
Procedure: Radiation Therapy

First Posted Date: 2006-10-11

Last Posted Date: 2013-10-21

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 19

Registration Number: NCT00385853

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

Calcium Supplementation for a Healthy Weight-Lite (CaSHeW Lite)

Not Applicable

Completed

Conditions: Obesity
Overweight

Interventions: Dietary Supplement: Reduced energy (lite) OJ fortified with Calcium and Vitamin D
Dietary Supplement: Reduced energy (lite) OJ without Calcium and Vitamin D
Behavioral: Nutrition Counseling

First Posted Date: 2006-10-11

Last Posted Date: 2017-01-10

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 83

Registration Number: NCT00386672

Locations: 🇺🇸
Massachusetts General Hospital Weight Center, Boston, Massachusetts, United States

Study of the Effects of Risperdal Consta on Brain Reward Circuitry Function, Craving and Cocaine Use in Active Cocaine Dependence

Phase 2

Completed

Conditions: Cocaine Dependence

Interventions: Drug: Risperidone
Drug: Placebo

First Posted Date: 2006-10-11

Last Posted Date: 2017-04-28

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 31

Registration Number: NCT00385801

Locations: 🇺🇸
MGH Addiction Research Program, Boston, Massachusetts, United States

Recombinant Hyaluronidase in Out-of-Hospital Setting: The EASI Access Trial

Phase 3

Completed

Conditions: Mass Casualty Incident
Dehydration

Interventions: Other: hypodermoclysis via recombinant hyaluronidase-facilitated subcutaneous infusion

First Posted Date: 2006-10-11

Last Posted Date: 2008-03-13

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 20

Registration Number: NCT00386386

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

The Effects of Nicotine on Cognition in Schizophrenia

Phase 4

Completed

Conditions: Schizophrenia

Interventions: Drug: Transdermal Nicotine Patch

First Posted Date: 2006-10-03

Last Posted Date: 2017-04-28

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 60

Registration Number: NCT00383747

Locations: 🇺🇸
Massachusetts General Hospital Schizophrenia Research Program, Boston, Massachusetts, United States

Pulsatile GnRH in Anovulatory Infertility

Phase 2

Conditions: Kallmann's Syndrome
Hypogonadotropic Hypogonadism
Amenorrhea

Interventions: Drug: GnRH
Device: Pump

First Posted Date: 2006-10-03

Last Posted Date: 2017-07-12

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 270

Registration Number: NCT00383656

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

Ziprasidone for the Treatment of Generalized Anxiety in Patients With Bipolar Disorder

Phase 4

Terminated

Conditions: Generalized Anxiety Disorder
Bipolar Disorder

Interventions: Drug: Placebo
Drug: Ziprasidone

First Posted Date: 2006-09-11

Last Posted Date: 2014-04-16

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 3

Registration Number: NCT00374543

Locations: 🇺🇸
Center for Anxiety and Traumatic Stress Disorders at Massachusetts General Hospital, Boston, Massachusetts, United States

The Treatment of Insomnia in Symptomatic Peri- and Postmenopausal Women

Not Applicable

Completed

Conditions: Menopause
Insomnia

Interventions: Drug: Eszopiclone
Drug: Placebo

First Posted Date: 2006-09-11

Last Posted Date: 2009-08-10

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 67

Registration Number: NCT00374192

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

Gemcitabine, Bevacizumab and Erlotinib in Pancreatic Cancer

Phase 2

Completed

Conditions: Pancreatic Cancer
Adenocarcinoma of the Pancreas

Interventions: Drug: Bevacizumab
Drug: Erlotinib
Drug: Gemcitabine

First Posted Date: 2006-08-21

Last Posted Date: 2017-05-15

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 32

Registration Number: NCT00366457

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy